Board of Directors

Lindsay A. Rosenwald, MD

Executive Chairman of the Board of Directors

Dr. Rosenwald has served as our Executive Chairman of the Board of Directors since inception. He has been Chairman and CEO of Fortress Biotech since December 2013. Since November 2008, Dr. Rosenwald has served as Co-Portfolio Manager and Partner of Opus Point Partners Management, LLC (“Opus Point”), an asset management firm in the life sciences industry, which he joined in 2009. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 23 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine.

Lucy Lu, MD

President and Chief Executive Officer

Dr. Lu has been our President and Chief Executive Officer since inception. From February 2012 to June 2017, Dr. Lu was the Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. From February 2007 through January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of the firm in February 2006. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee’s College of Arts and Science.

Jaideep Gogtay, MD


Dr. Gogtay joined our Board of Directors in February 2019.  Dr. Gogtay, 52, completed his medical graduation (M.B., B.S) from Grant Medical College and Sir J J Group of Hospitals in Mumbai. He then completed his M.D, in Pharmacology from Seth GS Medical College and KEM Hospital. During his post graduate days, he worked as a lecturer in pharmacology. Since 1994, he has been working with Cipla Ltd. where he currently serves as Global Chief Medical Officer. He has closely been involved in the development and introduction of several drugs in various therapeutic fields, particularly HIV/AIDS, infectious diseases and respiratory diseases. He has worked on several clinical trials in the field of asthma and Chronic Obstructive Pulmonary Disease and infectious diseases. He was involved in setting up the Chest Research Foundation (CRF). This Foundation is now an independent research center dedicated to conducting research in the field of respiratory medicine.  He has participated and spoken at several national and international forums, and has been actively involved in educational activities. He was a member of the Association of Physicians of India guidelines 2005 on ‘Antiretroviral Therapy’ and has 40 publications and has presented at over 50 conferences. He has also participated in research methodology workshops with academic institutes.

Neil Herskowitz


Mr. Herskowitz joined our Board of Directors in December 2015. Mr. Herskowitz has served as the managing member of the ReGen Group of companies, located in New York, since 1998, which include ReGen Capital Investments LLC and Riverside Claims Investments LLC. He has also served as the President of its affiliate, Riverside Claims LLC, since June 2004.  He also serves as Chairman of the board of directors of Starting Point Services for Children, a not-for-profit corporation. Mr. Herskowitz received a B.B.A. in Finance from Bernard M. Baruch College in 1978.

Jay Kranzler, MD, PhD


Dr. Kranzler joined our Board of Directors in February 2017.  Dr. Kranzler has been a Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. He is currently acting as Chief Executive Officer of Regenovation, a regenerative medicine company, and is a Board Member of Methylation Sciences, Pastorus, and ImmunoBrain Checkpoint, all companies focused on developing therapeutics for psychiatric or neurological disorders. Dr. Kranzler started his career at McKinsey & Company where he established the Firm’s pharmaceutical practice. He served as Chief Executive Officer (CEO) of Cytel Corporation, a company focused on the development of immunomodulatory drugs. Following Cytel, Dr. Kranzler became the CEO of Cypress Bioscience, where he was credited for the development of Savella™ (milnacipran) for the treatment of fibromyalgia. Dr. Kranzler was also Vice President, Head of External R&D Innovation and Worldwide R&D Strategic Investments at Pfizer. During his career, Dr. Kranzler has developed drugs, medical devices, as well as diagnostics, and is the inventor on over 30 patents. Dr. Kranzler graduated from Yale University School of Medicine with MD and PhD degrees with a focus in psychopharmacology.

Jeffrey Paley, MD


Dr. Paley joined our Board of Directors in December 2015. Dr. Jeffrey Paley has been an Active Clinician and Consultant in the healthcare industry for the past 18 years, during which time Dr. Paley has consulted for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Prior to his work for the buy-side, Dr. Paley consulted directly for several biotechnology and specialty pharmaceutical companies. Dr. Paley founded Access Medical Associates in 2003, after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders, including the landmark ACCORD study of intensive hyperglycemia, hypertension and hyperlipidemia management. He has served as a Director of Kellbenx, Retrophin and Remote Radiology Inc., Dr. Paley trained at Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital.

Nishant Saxena


Mr. Saxena joined our Board of Directors in February 2019. Mr. Saxena, 42, is the Global Chief Strategy Officer of Cipla Ltd., one of the largest pharmaceutical companies in India with revenues of $2.3 Billion, over 23,000 employees and presence in over 80 countries. He was previously Regional Chief Financial Officer of Cipla South Africa. Prior to that, he was an award-winning entrepreneur and worked with Procter & Gamble Company (“P&G”), the consumer goods giant. As one of industry’s leading strategist in the pharmaceutical space, he has to his credit two awards: ‘Young CFO of the Year’ and ‘Best In Class High Performance Team’.  He brings more than 18 years of corporate experience in strategy, finance and leadership. He previously worked with P&G in M&A, Finance and General Management. He has worked as an expat in Japan, Philippines, Singapore and South Africa, has done short stints in Australia, Korea, and China, and was consistently rated a top performer. Nishant started the National Award-Winning Elements Akademia and was profiled as a “Leader-in-Making” (Business World), “Path-Breaker CEO” (Economic Times), “India’s Hottest Start-Ups” (Business Today) and “One of 50 Social Entrepreneurs Making India Better” (Outlook Business). He was recognized by the World Bank for high-impact social entrepreneurship and for training and placing more than 10,000 unskilled youth. He also sits on the board of two not-for-profit organizations: P&G Alumni Foundation and IIM Amritsar.